These findings suggest that intrinsic biological properties of the tumor (such as ERBB2 and ESR1 expression, in line with previous findings5,6,10,50,51) seem to be the primary driver of response to neoadjuvant treatments as measured by pCR in tumors belonging to the same prognostic group according to our model. This evidence concerns the gene ERBB2 and neoplasm.